信迪利单抗联合培美曲塞治疗驱动基因阴性晚期非小细胞肺癌疗效观察  

Observation of the Effect of Sintilimab Combined with Pemetrexed in the Clinical Treatment of Advanced Non-small Cell Lung Cancer Patients with Negative Driver Genes

作　　者：温晶晶 陈金红 陈要强 Wen Jingjing;Chen Jinhong;Chen Yaoqiang(Department of Hematology and Oncology,Xinmi Traditional Chinese Medicine Hospital,Xinmi,Henan,452370,China)

机构地区：[1]新密市中医院血液肿瘤科,河南新密452370

出　　处：《黑龙江医学》2025年第9期1090-1093,共4页Heilongjiang Medical Journal

摘　　要：目的:探究信迪利单抗联合培美曲塞治疗驱动基因阴性晚期非小细胞肺癌(NSCLC)患者的临床效果。方法:回顾性分析2021年3月—2023年10月新密市中医院收治的84例晚期NSCLC患者的临床资料,根据治疗方式的不同将其分为两组,所有患者均接受培美曲塞+顺铂化疗,其中联合安慰剂治疗的40例患者作为对照组,联合信迪利单抗治疗的44例患者作为观察组。对比两组患者临床疗效、血清肿瘤标志物水平、免疫功能、生存质量、不良反应。结果:观察组患者客观缓解率(ORR)、疾病控制率(DCR)均高于对照组,差异均有统计学意义(χ^(2)=4.635、5.295,P<0.05);治疗后,观察组患者癌胚抗原(CEA)、糖类抗原125 (CA125)、糖类抗原199 (CA199)、细胞角蛋白19片段抗原21-1(CYFRA21-1)均低于对照组,差异均有统计学意义(t=8.419、21.002、5.555、10.069,P<0.001);治疗后,观察组患者CD3+、CD4+均高于对照组,CD8+低于对照组,差异均有统计学意义(t=10.644、3.550、6.837,P<0.05);治疗后,观察组患者健康调查量表(SF-36)中各维度评分均高于对照组,差异均有统计学意义(t=7.302、9.582、7.242、6.659、5.058,P<0.05);两组患者不良反应发生率比较,差异无统计学意义(χ^(2)=0.161,P>0.05)。结论:在驱动基因阴性晚期NSCLC患者中予以信迪利单抗+培美曲塞治疗可有效降低其血清肿瘤标志物水平,促进其免疫功能及生存质量改善,且安全可靠。Objective:To explore the letter dilip single combined therapy with pemetrexed drive rust resistance genes in advanced non-small cell lung cancer(NSCLC)patients with clinical effect.Methods:84 patients with advanced NSCLC admitted to Xinmi Hospital of Traditional Chinese Medicine from March 2021 to October 2023 were selected,and divided into two groups according to the random number table method.40 patients of control group were treated with pemetrexed and cisplatin chemotherapy,and 44 patients of the observation group were treated with sintilimab.The clinical efficacy,serum tumor marker level,immune function,quality of life,adverse reactions were compared.Results:ORR and DCR in the observation group were higher than those in the control group,and the differences were statistically significant(χ^(2)=4.635,5.295;P<0.05).After treatment,CEA,CA125,CA199 and CYFRA21-1 in observation group were lower than those in observation group,with statistically significant difference(t=8.419,21.002,5.555,10.069;P<0.05).After treatment,CD3+and CD4+in observation group were all higher,and CD8+was lower than observation group,with statistically significant difference(t=10.644,3.550,6.837;P<0.05).After treatment,the SF-36 scores in the observation group were higher than those in the control group,with statistically significant difference(t=7.302,9.582,7.242,6.659,5.058;P<0.05).There was no significant difference in the adverse reaction rate between the two groups(χ^(2)=0.161,P>0.05).Conclusion:Treatment with sindilizumab plus pemetrexed can effectively reduce the level of serum tumor markers,promote immune function and improve quality of life in patients with advanced NSCLC with negative driver genes,and it is safe and reliable.

关 键 词：驱动基因阴性 晚期非小细胞肺癌 信迪利单抗 培美曲塞 血清肿瘤标志物 免疫功能 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]